展開選單
About Us
Our Company
Team
Milestone & Recognitions
Partners and Collaborations
Research
Antroquinonol
Pipeline
Clinical Trials
Supporting Publications
About Alzheimer's Disease
News & Events
Press Releases
Events
Business Development
Contact Us
搜尋
繁中
EN
收合選單
搜尋
EN
繁體中文
English
HOME
News & Events
Press Releases
Press Releases
Apr 19, 2021
GoldenBiotech Completes Second Interim of Patients Enrollment for Covid-19 Phase 2 Clinical Trial_v1
Apr 07, 2021
GoldenBiotech Presents Outstanding Results of Potential Treatment for Relapsed AML in ASCO 2021
Jan 16, 2021
Covid-19 Drug Dual Achievements: GoldenBiotech’s New Drug Antroquinonol (HOCENA) Receives Positive Response from DMC Review and Licenses for 4 Countries
Jan 05, 2021
GoldenBiotech Signed First Licensing Agreement with BNC Korea for its New Drug Antroquinonol® (HOCENA®) to Treat Covid-19 in the Designated Territories
Nov 12, 2020
Breakthrough in AML Treatment_GoldenBiotech Reports Phas 2 Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed AML
Jun 29, 2020
GoldenBiotech's Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial IND
Mar 27, 2020
GoldenBiotech’s Antroquinonol Completed Phase 1 Trial and Started Phase 2 for Metastatic Pancreatic Cancer as First Line Treatment
May 27, 2022
FDA Approves GoldenBiotech's IND Application of Antroquinonol for Phase II Trial on Relapsed Acute Myeloid Leukemia (AML)
上一頁
1
2
下一頁